A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers
Status:
Completed
Trial end date:
2021-03-19
Target enrollment:
Participant gender:
Summary
This study is a single-centre, randomized, double-blind, placebo-controlled, dose escalation
study to assess the safety, tolerability and PK of GMA301 Injection in healthy subjects. Two
sequential dosing cohorts (at ascending dose fashion), each with 6 subjects receiving GMA301
Injection and 2 subjects receiving placebo (total of 16 subjects), will be given single
doses. The doses to be administered in the two cohorts will be 1500 mg and 2000 mg
respectively, or matching placebo